83 related articles for article (PubMed ID: 3917966)
1. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
[TBL] [Abstract][Full Text] [Related]
2. Opioid peptides in pseudocyesis.
Devane GW; Vera MI; Buhi WC; Kalra PS
Obstet Gynecol; 1985 Feb; 65(2):183-8. PubMed ID: 3918282
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
4. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
[TBL] [Abstract][Full Text] [Related]
5. The effect of naloxone on endogenous opioid regulation of pituitary gonadotropins and prolactin during the menstrual cycle.
Snowden EU; Khan-Dawood FS; Dawood MY
J Clin Endocrinol Metab; 1984 Aug; 59(2):298-302. PubMed ID: 6330154
[TBL] [Abstract][Full Text] [Related]
6. Naloxone interaction with pituitary response to TRH and LHRH test in patients with polycystic ovary syndrome.
Micić D; Popović V; Minić S; Sumarac M; Kendereski A; Damjanović S; Manojlović D; Mićić J
Endocrinol Exp; 1990 Mar; 24(1-2):187-93. PubMed ID: 2113856
[TBL] [Abstract][Full Text] [Related]
7. Alcohol effects on naloxone-stimulated luteinizing hormone, follicle-stimulating hormone and prolactin plasma levels in female rhesus monkeys.
Mello NK; Mendelson JH; Bree MP; Skupny A
J Pharmacol Exp Ther; 1988 Jun; 245(3):895-904. PubMed ID: 3133465
[TBL] [Abstract][Full Text] [Related]
8. Serotonin antagonist-induced lowering of prolactin secretion does not affect the pattern of pulsatile secretion of follicle-stimulating hormone and luteinizing hormone in the bitch.
Beijerink NJ; Kooistra HS; Dieleman SJ; Okkens AC
Reproduction; 2004 Aug; 128(2):181-8. PubMed ID: 15280557
[TBL] [Abstract][Full Text] [Related]
9. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
Barnes RB; Lobo RA
J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
11. Constancy of opioid control of luteinizing hormone in different pathophysiological states.
Lightman SL; Jacobs HS; Maguire AK; McGarrick G; Jeffcoate SL
J Clin Endocrinol Metab; 1981 Jun; 52(6):1260-3. PubMed ID: 6785301
[TBL] [Abstract][Full Text] [Related]
12. Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease.
Szilágyi A; Hole R; Keckstein J; Rossmanith WG
Gynecol Endocrinol; 1993 Sep; 7(3):159-66. PubMed ID: 8291452
[TBL] [Abstract][Full Text] [Related]
13. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome].
Zironi C; Pantaleoni M; Zizzo G; Coletta F; Velardo A
Minerva Ginecol; 1991 Oct; 43(10):443-7. PubMed ID: 1685015
[TBL] [Abstract][Full Text] [Related]
17. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model].
Tresguerres JA; Esquifino AI
Acta Physiol Lat Am; 1983; 33(3):257-74. PubMed ID: 6424409
[TBL] [Abstract][Full Text] [Related]
18. Opioid-dopaminergic interactions in primary empty sella.
Mancini A; Conte G; Fiumara C; Fabrizi ML; Iacona T; Zuppi P; Colosimo C; De Marinis L
Exp Clin Endocrinol; 1993; 101(5):277-82. PubMed ID: 8299703
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic control of gonadotrophin secretion in normal women and in patients with pathological hyperprolactinaemia.
Ho KY; Smythe GA; Lazarus L
Clin Endocrinol (Oxf); 1984 Jan; 20(1):53-63. PubMed ID: 6420095
[TBL] [Abstract][Full Text] [Related]
20. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome.
Quigley ME; Rakoff JS; Yen SS
J Clin Endocrinol Metab; 1981 Feb; 52(2):231-4. PubMed ID: 7462389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
